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Background
IFN alpha is an important cytokine of the immune system.
It has the ability to interfere with virus replication exerting
antiviral activity. Moreover, it displays antiproliferative
activity and can profoundly modulate the immune
response. IFN4N (or hyperglycosylated IFN alpha) is an
IFN-alpha2b mutein developed in our laboratory using
glycoengineering strategies. This molecule contains 4
potential N-glycosylation sites together with the natural
O-glycosylation site in Thr106 [1]. The resulting N- and
O-glycosylated protein shows higher apparent molecular
mass and longer plasmatic half-life compared to the non-
glycosylated IFN-alpha produced in bacterial systems and
used for clinical applications. As a consequence, the
correct glycosylation of our modified cytokine is very
important for its in vivo activity. For this reason, it is of
great relevance the evaluation of different mammalian
host cells for its production. While hamster-derived CHO
cells are widely used for large scale production of recombi-
nant therapeutic glycoproteins, human HEK cells are a
promising system because they are easy to grow and trans-
fect [2]. In this work, we performed a comparison between
both production systems in terms of cell growth, culture
parameters and specific productivity of hyperglycosylated
IFN alpha.
Results
Lentiviral vectors containing the sequence of IFN4N
were assembled and employed for the transduction of
CHO-K1 and HEK 293T cells. The recombinant cell
lines were subjected to a process of selective pressure
using increasing concentrations of puromycin. The
CHO-IFN4N and HEK-IFN4N producing cell lines
resistant to the highest concentration of puromycin
showed the highest productivity of IFN4N. In particular,
the CHO-IFN4N cell line was resistant to 350 μg/ml of
puromycin and it showed a specific productivity of
817 ± 134 ng.106cell-1.day-1, which represents an 8-fold
increment compared to the parental line. The HEK-
IFN4N cell line was resistant to 200 ug/ml of puromycin
and showed a 15-fold increment in the specific produc-
tivity compared to the parental line, reaching a value of
1,490 ± 332 ng.106cell-1.day-1. In both cases, complete cul-
ture death was achieved at higher puromycin concentra-
tions. The specific productivity of IFN4N of HEK 293T cell
line duplicated the value obtained for the CHO-K1 cell
line, and it was achieved at a lower concentration of puro-
mycin, making the selection process shorter (Figure 1).
Both cell lines were cloned using the limiting dilution
method, and after 15 days of culture more than 100 clones
were screened. To achieve the characterization and study
both cell lines as recombinant protein expression hosts,
the 6 best producer clones were isolated and amplified.
The adherent clones were grown for 7 days in order to
construct their growth curves. Cell density and viability
were determined every 24 h by trypan-blue exclusion
method and the culture supernatant was collected to
determine IFN4N and metabolites concentration. The
IFN4N production was assessed employing a sandwich
ELISA assay developed in our laboratory. Glucose con-
sumption and lactate production were evaluated using
specific Reflectoquant® test strips (Merck Millipore) in a
RQflex® Reflectometer (Merck Millipore). Levels of amo-
nium in the culture supernatant were determined by the
Berthelot reaction.
As shown in Table 1, the average specific growth rates of
CHO and HEK clones were similar. However, CHO clones
reached higher maximum cell densities (between 7.105-
1.5.106 cell.ml-1) than HEK clones (between 6.105-9.105 cell.
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ml-1), probably because of space limitation and higher glu-
cose consumption, since average qgluc of HEK clones was
higher (see Table 1). No differences were observed between
lactate and ammonium production of both groups of
clones. In contrast, specific production rate of IFN4N was
higher for the clones derived from the human cell line.
Moreover, higher average IFN4N cumulative production
for HEK clones was achieved after 7 days of culture (3,494
versus 5,961 ng.ml-1).
Conclusion
CHO and HEK cells were genetically modified to pro-
duce IFN4N by using lentiviruses as a tool for the
IFN4N gene transfer. Since both cell lines expressed
high levels of IFN4N, 6 clones were amplified for an
intensive characterization. Culture and production prop-
erties of both groups of clones were very different. On
the one hand, CHO clones were easy to maintain in cul-
ture for a long period of time, reaching higher cell den-
sities than HEK clones. On the other hand, the best
specific productivity of IFN4N was achieved employing
HEK cells. The behavior of CHO and HEK cells at large
scale production should be analyzed in order to select
the proper system for the cytokine’s production.
Wide differences have been observed between the glyco-
sylation profile of the same recombinant therapeutic pro-
tein produced in CHO and HEK systems [2]. Considering
that glycosylation affects protein bioactivity, stability,
Figure 1 Comparison between the specific productivity of the CHO-IFN4N (a) and HEK-IFN4N (b) producing cell lines as a function of
puromycin concentration.
Table 1 Determination of the specific cell growth rate, specific production rate of lactate, ammonium and IFN4N, and










P4D3 0,0182 ± 0,002 79 ± 8 36 ± 5 40 ± 5 0,027 ± 0,007
P1E9 0,0196 ± 0,002 35 ± 4 24 ± 4 45 ± 5 0,027 ± 0,003
P2A9 0,0249 ± 0,001 41 ± 4 30 ± 2 31 ± 1 0,014 ± 0,004
P1B6 0,0240 ± 0,002 19 ± 3 26 ± 5 49 ± 5 0,013 ± 0,005
P1B7 0,0191 ± 0,002 41 ± 3 32 ± 4 35 ± 2 0,017 ± 0,006










P2A5 0,020 ± 0,001 129 ± 10 56 ± 6 37 ± 4 0,014 ± 0,003
P2C7 0,015 ± 0,002 122 ± 13 62 ± 11 38 ± 3 0,009 ± 0,003
P2G11 0,017 ± 0,002 82 ± 6 47 ± 9 31 ± 3 0,008 ± 0,002
P3B7 0,016 ± 0,002 99 ± 8 55 ± 8 31 ± 3 0,008 ± 0,003
P3H8 0,027 ± 0,001 82 ± 11 46 ± 6 34 ± 3 0,008 ± 0,001
P4B4 0,017 ± 0,002 63 ± 5 61 ± 15 32 ± 3 0,009 ± 0,001
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pharmacokinetics and immunogenicity, it would be very
important to evaluate the characteristics of the IFN4N
produced in both hosts to determine their efficacy as ther-
apeutic agents.
Published: 4 December 2013
References
1. Ceaglio N, Etcheverrigaray M, Conradt HS, Grammel N, Kratje R, Oggero M:
Highly glycosylated human alpha interferon: An insight into a new
therapeutic candidate. J Biotechnol 2010, 146:74-83.
2. Croset A, Delafosse L, Gaudry JP, Arod C, Gleza L, Losbergera C, Beguea C,
Krstanovicb A, Robertb F, Vilboisa F, Chevaleta L, Antonssona B: Differences
in the glycosylation of recombinant proteins expressed in HEK and CHO
cells. J Biotechnol 2012, 161:336-348.
doi:10.1186/1753-6561-7-S6-P33
Cite this article as: Gugliotta et al.: Differences in the production of
hyperglycosylated IFN alpha in CHO and HEK 293 cells. BMC Proceedings
2013 7(Suppl 6):P33.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gugliotta et al. BMC Proceedings 2013, 7(Suppl 6):P33
http://www.biomedcentral.com/1753-6561/7/S6/P33
Page 3 of 3
